证券代码：430300 证券简称：辰光医疗 公告编号：2025-048 上海辰光医疗科技股份有限公司 关于公司取得发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"、"辰光医疗"）近日取 得国家知识产权局颁发 2 项《发明专利证书》，具体情况如下： 1、发明名称：一种用于磁共振成像的零焊点柔性射频线圈结构 专利号：ZL 2021 1 0508355.1 专利申请日：2021 年 04 月 27 日 专利权人：上海辰光医疗科技股份有限公司 地址：201707 上海市青浦区华青路 1269 号 授权公告号：CN 113109750 B 该专利属于医用磁共振技术领域。本发明提供一种用于磁共振成像的零焊点 柔性射频线圈结构，进一步降低磁共振射频线圈的厚度和重量，提高其可靠性、 柔软性和舒适度。 2、发明名称：一种分布式电容的磁共振射频发射线圈结构 专利号：ZL 2021 1 0728221.0 （二）《发明专利证书》（证书号第 790 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-049 上海辰光医疗科技股份有限公司 2024 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日 在北京证券交易所信息披露平台（www.bse.cn）披露了《2024 年年度报告》（公 告编号：2025-023），为方便广大投资者更深入了解公司 2024 年年度经营业绩的 具体情况，加强与投资者的互动交流，公司拟召开 2024 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2025 年 5 月 13 日（星期二）下午 15：00-17:00。 （二）会议召开地点 本次年报业绩说明会将采用网络远程的方式举行，投资者可登录全景网"投 资者关系互动平台"（http://ir.p5w.net）参与本次年报业绩说明会。 三、 参加人员 董事长、总经理：王杰 先生 董事、副总经理：王为 先生 董事会 ...

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and specialized magnets in high-tech fields [1] - The company has a market capitalization of 1.509 billion yuan and a latest price-to-book ratio of 6.88 [1] - The company reported a revenue of 25.0744 million yuan in Q1 2025, representing a year-on-year increase of 20.21%, while the net profit was -8.5827 million yuan, a year-on-year decrease of 5.22% [1] Group 2 - The company has received several recognitions, including being named a "Technology Little Giant" enterprise in Shanghai and a national-level "Specialized and New" small giant enterprise [1] - The company’s sales gross margin stands at 30.84% [1] - The company experienced a net inflow of 8.4283 million yuan in main funds on May 6, with a total inflow of 15.8293 million yuan over the past five days [1]

证券代码：430300 证券简称：辰光医疗 公告编号：2025-046 上海辰光医疗科技股份有限公司 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 27 日 2.会议召开地点：上海辰光医疗科技股份有限公司 三楼会议室 3.会议召开方式：现场会议 4.发出监事会会议通知的时间和方式：2025 年 4 月 22 日以书面、电话和微信方 式发出 5.会议主持人：监事长 ZHAO HUAWEI（赵华炜）先生 6.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合有关法律法规、规范性文件和《公司章程》 的规定，所做决议合法有效。 （二）会议出席情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 二、议案审议情况 （一）审议通过《2025 年第一季度报告》议案 1.议案内容： 根据相关法律法规、规范性文件及《公司章程》规定，结合公司 2025 年第 一季度的经营情况，公司编 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-045 上海辰光医疗科技股份有限公司 第五届董事会第十八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 4 月 27 日 2.会议召开地点：上海辰光医疗科技股份有限公司 三楼会议室 3.会议召开方式：现场会议 （二）会议出席情况 4.发出董事会会议通知的时间和方式：2025 年 4 月 22 日以书面、电话和微 信方式发出 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 5.会议主持人：董事长 王杰先生 6.会议列席人员：监事、高级管理人员 （一）审议通过《2025 年第一季度报告》 1.议案内容： 7.召开情况合法、合规、合章程性说明： 会议的召集、召开和表决程序符合有关法律法规、规范性文件和《公司章程》 的规定。 3.回避表决情况： 本议案不涉及回避表决。 4.提交股东会表决情况： 本议案无需提交股东会审议。 根据相关法律 ...

Financial Performance - Revenue for the first quarter of 2025 increased by 20.21% to CNY 25,074,439.29, up from CNY 20,859,112.75 in the same period last year[10] - Net profit attributable to shareholders was a loss of CNY 8,582,701.78, an improvement of 5.22% compared to a loss of CNY 9,055,465.07 in Q1 2024[10] - Operating profit for Q1 2025 was a loss of ¥8,406,525.58, an improvement from a loss of ¥9,192,281.87 in Q1 2024[43] - Net profit for Q1 2025 was a loss of ¥8,582,701.78, compared to a loss of ¥9,055,465.07 in Q1 2024, showing a reduction in losses of approximately 5.2%[43] - The company reported a total operating profit of -¥6,628,413.05 for Q1 2025, slightly better than -¥6,982,801.43 in Q1 2024[45] Cash Flow - Operating cash flow improved significantly, with a net cash flow from operating activities of -CNY 8,197,355.91, a 50.94% reduction in cash outflow compared to -CNY 16,709,112.46 in the previous year[10] - Cash flow from operating activities for Q1 2025 was -¥8,197,355.91, an improvement compared to -¥16,709,112.46 in Q1 2024[47] - Total cash inflow from investment activities in Q1 2025 was ¥16,019,239.45, while cash outflow was ¥36,802,279.30, resulting in a net cash flow of -¥20,783,039.85[48] - Cash inflow from financing activities in Q1 2025 was ¥12,000,000.00, compared to ¥17,000,000.00 in Q1 2024, showing a decrease of approximately 29.4%[48] Assets and Liabilities - Total assets decreased by 2.00% to CNY 432,625,004.90 as of March 31, 2025, compared to CNY 441,465,037.83 at the end of 2024[10] - Total liabilities as of March 31, 2025, were ¥213,125,853.60, compared to ¥213,383,184.75 on December 31, 2024, showing a slight decrease of 0.12%[36] - The company's total equity decreased to ¥219,499,151.30 from ¥228,081,853.08, a reduction of approximately 3.77%[36] - Total current assets amounted to ¥240,677,602.73, a decrease from ¥247,334,903.32 on December 31, 2024, representing a decline of approximately 2.66%[34] Shareholder Information - The total number of ordinary shares remained at 85,847,126, with 6,488 shareholders[17] - Major shareholder Wang Jie holds 27.22% of the shares, while Tian Lifeng holds 5.71%[19] Operating Costs and Expenses - The company's gross profit margin decreased due to a 70.24% increase in operating costs, which outpaced revenue growth[11] - Total operating costs for Q1 2025 were ¥36,275,290.39, up from ¥30,698,379.49 in Q1 2024, indicating an increase of about 18.0%[41] - Research and development expenses for Q1 2025 were ¥7,231,154.86, compared to ¥6,033,462.71 in Q1 2024, indicating an increase of approximately 19.9%[41] Guarantees and Commitments - The company provided external guarantees totaling ¥30,000,000, with a remaining balance of ¥20,000,000[28] - The company has fulfilled its commitments regarding external guarantees and other major related transactions in a timely manner[25] Other Financial Information - The company reported a credit impairment loss of ¥1,105,592.94 in Q1 2025[43] - The company has no litigation or arbitration matters during the reporting period[24] - The company has no significant related party transactions that were not disclosed[24]

Financial Performance - The company reported a basic earnings per share of -0.7100 yuan for 2024, a decrease of 407.14% compared to -0.1400 yuan in 2023 [1] - The net profit for 2024 was -0.61 billion yuan, representing a decline of 408.33% from -0.12 billion yuan in 2023 [1] - Operating revenue decreased by 28.31% to 1.19 billion yuan in 2024 from 1.66 billion yuan in 2023 [1] - The return on equity was -23.56% in 2024, a significant drop from -3.95% in 2023 [1] - The net asset per share decreased by 21.07% to 2.66 yuan in 2024 from 3.37 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 19.7735 million shares, accounting for 32.91% of the circulating shares, with a decrease of 2.7696 million shares compared to the previous period [2] - Shanghai Tiancong Enterprise Management Center (Limited Partnership) holds 600.00 thousand shares, representing 9.98% of the total share capital, with no change [2] - Tian Lifeng holds 490.52 thousand shares, accounting for 8.16% of the total share capital, with no change [2] - New entrants to the top ten shareholders include Cha Qin and Wang Guolin, holding 180.00 thousand shares (3.00%) and 60.28 thousand shares (1.00%) respectively [2] - Shareholders Luo Wen and Yu Haihong have exited the top ten shareholders list [2] Dividend Policy - The company has announced no distribution or capital increase for the current period [3]

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields [1] - The company has received several recognitions, including being named a "Technology Little Giant" enterprise in Shanghai and a national-level "Specialized and Innovative" small giant enterprise [1] - The latest financial results show a revenue of 86.11 million yuan for the third quarter of 2024, representing a year-on-year decrease of 13.44%, with a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] Group 2 - The company's current price-to-earnings (P/E) ratio is -25.68, with a price-to-book (P/B) ratio of 5.45 and a total market capitalization of 1.489 billion yuan [2] - The industry average P/E ratio is 48.08, while the industry median is 30.21, indicating that the company is significantly below industry benchmarks [2] - The company has experienced a net outflow of 15.09 million yuan in principal funds on April 22, with a total outflow of 40.22 million yuan over the past five days [1]

Group 1 - The core business of the company is the research, production, and sales of superconducting MRI systems and special magnets in high-tech fields [1] - The company has received several recognitions, including "Technology Little Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" at both municipal and national levels [1] - The latest financial results show a revenue of 86.11 million yuan for the third quarter of 2024, representing a year-on-year decrease of 13.44%, with a net loss of approximately 15.88 million yuan, a year-on-year decline of 129.77% [1] Group 2 - The company's current price-to-earnings (PE) ratio is -26.85, with a price-to-book (PB) ratio of 5.70 and a total market capitalization of 1.557 billion yuan [2] - The industry average PE ratio is 45.94, while the industry median is 29.64, indicating that the company is significantly below industry averages [2] - The company has experienced a net outflow of 16.31 million yuan in principal funds on April 16, with a total outflow of 17.75 million yuan over the past five days [1]

4月14日，辰光医疗今日收盘20.21元，上涨3.59%，最新市净率6.35，总市值17.35亿元。 资金流向方面，4月14日，辰光医疗主力资金净流入838.77万元，近5日总体呈流入状态，5日共流入 4001.37万元。 最新一期业绩显示，2024年三季报，公司实现营业收入8610.63万元，同比-13.44%；净利 润-15875336.84元，同比-129.77%，销售毛利率41.27%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13辰光医疗-29.91-29.916.3517.35亿行业平均 45.7149.434.75102.82亿行业中值29.9929.792.3746.97亿1硕世生物-1863.40-1863.401.1738.50亿2诺唯 赞-532.18-532.182.4496.29亿3博晖创新-364.57-224.464.0255.96亿4康泰医学-267.7531.412.7452.07亿5华 大基因-201.24220.132.08204.50亿6奥精医疗-109.83-109.831.4019.90亿7睿昂基因-80.13-80.131.2511.59亿 8热景生 ...